Patent Application
20220242913
The present invention relates to a novel intermediate used for physiologically active polypeptides and a method for preparing the same. More specifically, the present invention relates to a method for preparing a physiologically active polypeptide in a safer and more effective manner, a novel polypeptide intermediate used therefor, and a method for preparing the same.
Diabetes-related diseases, including obesity and type 2 diabetes, are among the typical metabolic diseases developing in modern society, and are recognized as an important threat to health worldwide. Accordingly, economic costs are also increasing rapidly.
Research has been conducted on the development of pharmaceuticals that can be used for the treatment of obesity and diabetes, but these have the disadvantages of showing fatal side effects or having insignificant effects on the treatment of obesity. Therefore, research that can solve the problems arising with conventional therapeutics is actively underway, and recently, much attention has been paid to glucagon derivatives. Glucagon is produced in the pancreas when the blood glucose levels fall due to reasons such as medications, diseases, deficiency in hormones or enzymes, etc. Glucagon sends a signal for glycogen breakdown in the liver to induce the release of glucose and increases blood glucose to a normal level. In addition to the effect of increasing the blood glucose levels, glucagon suppresses appetite and activates hormone-sensitive lipase of adipocytes to promote lipolysis, thereby showing an anti-obesity effect. Various studies related to glucagon are underway.
In one example, Korean Laid-Open Publication No. 10-2017-0080521 discloses a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof. Such a peptide may be composed of substitution, addition, deletion, modification, and combinations thereof in at least one or more amino acids in the native glucagon sequences, and more specifically, it discloses an isolated peptide including the amino acid sequence represented by the following General Formula 1:
The peptide may be prepared by way of methods known in the art, for example, synthesis via an automatic peptide synthesizer, genetic manipulation technique, or any other methods, depending on the length of the peptide. In order to use the peptides prepared by way of these various production methods as pharmaceuticals, the quality of high purity, a yield suitable for commercialization, and a production process suitable for mass production are required.
Therefore, there is a need for a novel polypeptide intermediate that enables the efficient production of such physiologically active polypeptides and an efficient production method capable of providing the same. Accordingly, the present inventors have completed the present invention by developing a novel polypeptide intermediate and a method for preparing the same, as a result of research on a method for preparing a physiologically active polypeptide more safely and efficiently.
It is one object of the present invention to provide a novel polypeptide intermediate and a resin composite compound used for physiologically active polypeptides.
It is another object of the present invention to provide a method for efficiently preparing the novel polypeptide intermediate and resin composite compound.
It is still another object of the present invention to provide a method for efficiently preparing a physiologically active polypeptide used for the novel polypeptide intermediate.
In order to achieve the above objects, one aspect of the present invention provides a novel polypeptide intermediate represented by Chemical Formula 1 below:
R-cyclo(Glu-Lys-Arg-Ala-Lys)-Glu-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Cys-X:
wherein, R is selected from the group consisting of H, linear or branched C1-12 alkyl, linear or branched C1-12 alkyloxycarbonyl, linear or branched C2-12 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, C6-12 aryl, C6-12 aryloxycarbonyl, C1-6 alkyl C6-12 aryl, C1-6 alkyl C6-12 aryloxycarbonyl, and heteroaryl; X is selected from the group consisting of H, linear or branched C1-12 alkyl, linear or branched C1-12 alkyloxycarbonyl, linear or branched C2-12 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, C6-12 aryl, C6-12 aryloxycarbonyl, C1-6 alkyl C6-12 aryl, C1-6 alkyl C6-12 aryloxycarbonyl, and heteroaryl; and these substituents may be further substituted with one or more identical or different substituents selected from the group consisting of H, halogen, cyano, linear or branched C1-6 alkyl, linear or branched C2-10 alkenyl, C3-10 cycloalkyl, halo C1-5 alkyl, hydroxy C1-6 alkyl, amino, mono or di C1-6 alkylamino, oxo, hydroxy, C1-6 alkoxy, C6-12 arylsulfonyl, and C1-6 alkylsulfonyl.
Additionally, in one embodiment of the present invention, there is provided a novel resin composite compound represented by Chemical Formula 3 below:
wherein A to D are protecting groups; A to D are each independently selected from the group consisting of triphenylmethyl (Trt), tert-butyl (tBu), t-butyloxycarbonyl (Boc), and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf); R is selected from the group consisting of H, linear or branched C1-12 alkyl, linear or branched C1-12 alkyloxycarbonyl, linear or branched C2-12 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, C6-12 aryl, C6-12 aryloxycarbonyl, C1-6 alkyl C6-12 aryl, C1-6 alkyl C6-12 aryloxycarbonyl, and heteroaryl; X′ is a resin; and these substituents may be further substituted with one or more identical or different substituents selected from the group consisting of H, halogen, cyano, linear or branched C1-6 alkyl, linear or branched C2-10 alkenyl, C3-10 cycloalkyl, halo C1-5 alkyl, hydroxy C1-6 alkyl, amino, mono or di C1-6 alkylamino, oxo, hydroxy, C1-6 alkoxy, C6-12 arylsulfonyl, and C1-6 alkylsulfonyl.
Additionally, in one embodiment of the present invention, there is provided a method for preparing a resin composite compound represented by Chemical Formula 3 below, including the steps of:
(1) swelling a resin in a polar aprotic solvent; (2) preparing a deprotected resin by removing the protecting group using a piperidine solution in a polar aprotic solvent; (3) activating the protected amino acid by adding the protected amino acid, 1-hydroxy-1H-benzotriazole, and 1,3-diisopropylcarbodiimide in a polar aprotic solvent; (4) coupling by adding an activated protected amino acid solution to the deprotected resin in a reactor; (5) repeating steps (2)-(4) until a peptide is formed; (6) preparing a partially deprotected resin by reacting the synthesized peptide with tetrakispalladium, N-methylaniline, and phenylsilane in a solvent; and (7) cyclizing the synthesized peptide by adding a coupling reagent in a polar aprotic solvent:
wherein A to D are protecting groups; A to D are each independently selected from the group consisting of triphenylmethyl (Trt), tert-butyl (tBu), t-butyloxycarbonyl (Boc), and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf); R is selected from the group consisting of H, linear or branched C1-12 alkyl, linear or branched C1-12 alkyloxycarbonyl, linear or branched C2-12 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, C6-12 aryl, C6-12 aryloxycarbonyl, C1-6 alkyl C6-12 aryl, C1-6 alkyl C6-12 aryloxycarbonyl, and heteroaryl; X′ is a resin; and these substituents may be further substituted with one or more identical or different substituents selected from the group consisting of H, halogen, cyano, linear or branched C1-6 alkyl, linear or branched C2-10 alkenyl, C3-10 cycloalkyl, halo C1-5 alkyl, hydroxy C1-6 alkyl, amino, mono or di C1-6 alkylamino, oxo, hydroxy, C1-6 alkoxy, C6-12 arylsulfonyl, and C1-6 alkylsulfonyl.
Additionally, in one embodiment of the present invention, there is provided a method for preparing a physiologically polypeptide and a pharmaceutically acceptable salt thereof, including the steps of:
(1) preparing a deprotected resin by removing the protecting group of the cyclized peptide compound prepared by way of the above method using a piperidine solution in a polar aprotic solvent; (2) activating the protected amino acid by adding the protected amino acid, 1-hydroxy-1H-benzotriazole, and 1,3-diisopropylcarbodiimide in a polar aprotic solvent; (3) coupling by adding an activated protected amino acid solution to the deprotected resin in a reactor; (4) repeating steps (1)-(3) until a peptide is formed; (5) deprotecting the protected resin using a cleavage cocktail while simultaneously cleaving the desired peptide from the resin; and (6) filtering the cleaved mixture from the resin.
In one embodiment of the present invention, there is provided a method for preparing a physiologically active polypeptide represented by Chemical Formula 2 below and a pharmaceutically acceptable salt thereof:
H-His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Ser-Lys-Tyr-Leu-Asp-cyclo(Glu-Lys-Arg-Ala-Lys)-Glu-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Cys-NH2;
wherein the method for preparing a physiologically active polypeptide represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof includes:
(1) a reaction step of obtaining a peptide-resin composite by reacting the resin composite compound of Chemical Formula 3 with an amino acid; and
(2) a cleavage step of cleaving the physiologically active polypeptide of Chemical Formula 2 from the peptide-resin composite.
The novel polypeptide intermediate and the method for preparing the same according to the present invention can provide a novel polypeptide intermediate that can be used for physiologically active polypeptide pharmaceuticals, and are suitable for mass production and have the advantage of being able to produce efficient and high-quality products with reproducibility.
The method for preparing the novel polypeptide intermediate of the present invention will be described in more detail step by step as follows.
The protecting group of the amino acid used herein may be any one which has stability under the conditions of the peptide condensation reaction, can be easily removed, does not affect the peptide chain and the substituents during the removal reaction, and does not cause racemization of any chiral center present in the peptide. Examples of the suitable protecting groups include 9-fluorenylmethyloxycarbonyl (Fmoc), 2-(4-nitrophenyl-sulfonyl)ethoxycarbonyl (NSC), t-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), biphenylisopropyl-oxycarbonyl, t-amyloxycarbonyl, isobornyloxycarbonyl, (α,α)-dimethyl-3,5-dimethoxybenzyloxycarbonyl, 0-nitrophenylsulfenyl, 2-cyano-t-butyloxycarbonyl, etc., but are not limited thereto, and other suitable protecting groups known in the art for this purpose may also be used within the scope of the present invention. Preferably, 9-fluorenylmethyloxycarbonyl (Fmoc) or t-butoxycarbonyl (Boc) may be used.
In addition, in one embodiment of the present invention, a solid-phase peptide synthesis method using 9-fluorenylmethoxycarbonyl (Fmoc) as an amino acid protecting group may be used among the amino acid protecting groups.
The resin used in all steps of the reaction of the present invention is a polymer support treated with an appropriate linker, and a polystyrene (PS)-based resin or a polystyrene-polyethylene glycol copolymer (PS-PEG copolymer)-based resin is preferable, but the resin is not limited thereto, and other suitable resins known in the art for this purpose may also be used within the scope of the present invention.
The resin that can be used in the present invention may include polystyrene (PS)-based resins such as aminomethyl resin, aminoethyl resin, aminobutyl resin, Rink amide aminomethyl resin, Rink amide aminoethyl resin, Rink amide aminobutyl resin, Rink amide MBHA resin, Rink amide resin, 2-chlorotrityl-N-Fmoc-hydroxylamine resin, HMPA-AM resin, HMPB resin, 2-chlorotrityl resin, 4-carboxytrityl resin, Wang resin, PAL resin, 4-(hydroxymethyl)phenoxyacetic acid resin, and Sieber amide resin, and polystyrene-polyethylene glycol copolymer-based resins such as such as TentaGel S resin, TentaGel R resin, TentaGel XV resin, TentaGel MB resin, TentaGel HL resin, TentaGel B resin, TentaGel M resin, TentaGel N resin, TentaGel PAP resin, Rink amide TentaGel S resin (TentaGel S RAM), Rink amide TentaGel R resin (TentaGel R RAM), Rink amide TentaGel XV resin (TentaGel XV−RAM), Rink amide TentaGel MB resin (TentaGel MB—RAM), Rink amide TentaGel HL resin (TentaGel HL RAM), Rink amide TentaGel B resin (TentaGel B RAM), Rink amide TentaGel M resin (TentaGel M RAM), Rink amide TentaGel N resin (TentaGel N RAM), Rink amide TentaGel PAP resin (TentaGel PAP RAM), and various substituted HypoGel 200 and 400 resins.
The polar aprotic solvent used in all steps of the reaction of the present invention may include, but is not limited to, for example, dimethylformamide, dimethylacetamide, etc., and other suitable polar aprotic solvents known in the art for this purpose may also be used within the scope of the present invention.
According to one embodiment of the present invention, the polar aprotic solvent used in all steps of the reaction of the present invention may be preferably selected from the group consisting of dimethylformamide, dimethylacetamide, and mixtures thereof.
Another aspect of the present invention provides a method for preparing a resin composite compound of Chemical Formula 3. The method for preparing the resin composite compound of the present invention includes the steps of:
(1) swelling a resin in a polar aprotic solvent;
(2) coupling by adding an activated and protected amino acid to the deprotected resin in a reactor;
(3) repeating step (2) until a peptide is formed;
(4) preparing a partially deprotected resin by reacting the synthesized peptide with tetrakispalladium, N-methylaniline, and phenylsilane in a solvent; and
(5) cyclizing the synthesized peptide by adding a coupling reagent in a polar aprotic solvent.
In the embodiment of the present invention, the method for preparing the peptide intermediate compound of Chemical Formula 1 and the resin of Chemical Formula 3 will be described in more detail step by step as follows.
In step (1), the resin is swollen in a polar aprotic solvent.
In order to obtain the deprotected resin of step (2), the deprotected resin may be prepared by removing the protecting group using, for example, a piperidine solution in a polar aprotic solvent.
More specifically, after the deprotection reaction for preparing the deprotected resin, the deprotected resin may be washed using a polar solvent. The polar solvent used herein may be selected from the group consisting of dimethylformamide, dimethylacetamide, methanol, ethanol, and mixtures thereof. Accordingly, the deprotected resin can be activated. In a more specific embodiment, the protected amino acid is activated by adding the protected amino acid, 1-hydroxy-1H-benzotriazole, and 1,3-diisopropylcarbodiimide in a polar aprotic solvent.
In step (2), a coupling reaction is performed by adding an activated protected amino acid solution to the deprotected resin in a reactor.
In a more specific embodiment, after the coupling reaction of step (4), the coupled resin may be washed using a polar solvent. The polar solvent used herein may be selected from the group consisting of dimethylformamide, dimethylacetamide, methanol, ethanol, and mixtures thereof.
In step (3), the above steps (1)-(2) are repeatedly performed until a peptide is formed.
The reaction of step (3) may be repeated 2 to 100 times until a peptide of a desired length is formed, preferably 10 to 50 times, and most preferably 14 to 30 times.
In step (4), a partially deprotected resin is prepared by reacting the synthesized peptide with tetrakispalladium, N-methylaniline, and phenylsilane in a solvent.
The solvent used in the reaction of step (4) may be selected from the group consisting of dichloromethane, chloroform, and mixtures thereof.
In step (5), a polypeptide intermediate is prepared by performing a cyclization reaction by adding the synthesized peptide and a coupling reagent in a polar aprotic solvent.
The coupling reagent used in the reaction of step (5) may be selected from 1-hydroxy-1H-benzotriazole/1,3-diisopropylcarbodiimide or HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]-pyridinium 3-oxide hexafluorophosphate)/N,N-diisopropylethylamine, but is not limited thereto, and other suitable coupling reagents known in the art for this purpose may also be used within the scope of the present invention.
Still another aspect of the present invention provides a method for preparing a physiologically active polypeptide represented by Chemical Formula 2 below or a pharmaceutically acceptable salt thereof from the method described above. The method for preparing a physiologically active polypeptide of Chemical Formula 2 and a pharmaceutically acceptable salt according to the present invention may include:
(1) a reaction step of obtaining a peptide-resin composite by reacting the resin composite compound of Chemical Formula 3 with an amino acid; and
(2) a cleavage step of cleaving the physiologically active polypeptide of Chemical Formula 2 from the peptide-resin composite:
H-His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Ser-Lys-Tyr-Leu-Asp-cyclo(Glu-Lys-Arg-Ala-Lys)-Glu-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Cys-NH2.
The method for preparing a physiologically polypeptide using the novel polypeptide intermediate of the present invention will be described in more detail step by step as follows. In step (1), an amino acid linking reaction is repeatedly performed until a peptide having a desired amino acid sequence is formed by reacting the resin composite compound of Chemical Formula 3 obtained by way of the above method or another method with an amino acid. The reaction of step (1) may be repeatedly performed 1 to 50 times until a peptide of a desired length is formed, and preferably 1 to 30 times.
In one embodiment of the present invention, the physiologically polypeptide of Chemical Formula 2 is in the form of a trifluoroacetic acid salt or an acetic acid salt.
In one embodiment of the method for preparing a physiologically active polypeptide of the present invention, the reaction step (1) described above may include a step of deprotecting the peptide-resin composite in a polar aprotic solvent. In a more specific embodiment, the polar aprotic solvent may be selected from the group consisting of dimethylformamide, dimethylacetamide, and mixtures thereof.
In one embodiment of the method for preparing a physiologically active polypeptide of the present invention, as the resin composite compound of Chemical Formula 3 used in the reaction step (1) described above, those in which X′ is a Rink amide resin may be used.
In step (2), the desired peptide is cleaved from the resin while deprotecting the protected resin using a cleavage cocktail simultaneously.
The cleavage cocktail of step (2) may include a solution of trifluoroacetic acid (TFA), at least one scavenger, and dichloromethane.
The scavenger of step (2) may be selected from the group consisting of triisopropylsilane (TIPS), triethylsilane (TES), phenol, anisole, thioanisole, water, ethanedithiol (EDT), 1-dodecanethiol, dithiothreitol (DTT), and indole, but is not limited thereto, and other suitable scavengers known in the art for this purpose may also be used within the scope of the present invention.
The preparation method of the present invention may further include a step of filtering the cleaved mixture from the resin after step (2).
The preparation method of the present invention provides the compound of Chemical Formula 1 and the resin composite compound of Chemical Formula 3, which are novel cyclized polypeptide intermediates that can be used as high-purity pharmaceutical intermediates. When the cyclized intermediate of the present invention is used, the improvement in yield and inhibition in impurity generation may be simultaneously achieved in the preparation of physiologically active polypeptides. In addition, as compared with the prior art, the generated related substances are changed to a type that can be easily separated from the product, so that the final purification can be easily performed to thereby obtain high-quality pharmaceuticals.
In the preparation of a polypeptide having a lactam ring, the process of the cyclization reaction after linear synthesis, which is a conventional method, will be compared in more detail with the preparation method of the present invention. In the prior art method, 16 to 30 amino acids were linearly synthesized in sequence, and each linearly synthesized polypeptide (16mer to 30mer) was subject to a cyclization reaction. However, in the prior art, as the length of the linearly synthesized polypeptide increased, the purity tended to decrease sharply. In addition, as the cyclization reaction was performed at the end, impurities were generated in excess, which further decreased the purity, and the removal of heavy metals used in the cyclization synthesis must be managed, making the final purification process very difficult. Accordingly, there was a large loss in yield.
The novel polypeptide intermediate according to the present invention and the physiologically active polypeptide prepared by way of the preparation method thereof are subjected to a cyclization reaction after preparing a linear polypeptide up to 15mer, and the remaining amino acids are further synthesized. Thus, it has the advantage of synthesizing high-purity products compared with the existing preparation method. Additionally, the preparation method of the present invention also improves the generation of related substances, and thus, the final purification process after completion of synthesis can be carried out easily, and the components of heavy metals can be easily managed. This is a beneficial effect beyond what is expected when simply changing the position of the lactam cyclization process, assuming that other factors remain unchanged. The preparation method of the present invention has the advantage being an efficient process suitable for commercial production because the overall yield and purity are greatly improved.
Hereinafter, preferred Examples are provided to aid understanding of the present invention. However, these Examples are provided for illustrative purposes only, and it is apparent to those skilled in the art that various modifications and variations are possible within the scope and spirit of the present invention.
Throughout the present specification, one-letter or three-letter codes are typically used for naturally occurring amino acids, and generally accepted three-letter codes are used for other amino acids, such as Aib (α-aminoisobutyric acid). In addition, amino acids referred to by abbreviation herein have been described according to the IUPAC-IUB nomenclature.
Solid-phase peptide synthesis methods (SPPS methods, including methods for deprotecting amino acids, methods for cleaving peptides from resins, and purification thereof), as well as methods for detection and characterization of the resulting peptides (LCMS, MALDI, and UPLC) method) are related.
The protected amino acid derivative used is the standard Fmoc-amino acid. The alpha amino group at the N-terminal amino acid has been protected with Boc (e.g., Boc-His(Boc)-OH, or Boc-His(Trt)-OH for peptides having His at the N-terminus).
80.0 g (0.31 mmol/g) of Rink amide MBHA resin and 480 mL of dimethylformamide were added to a vessel, stirred for 15 minutes, and then filtered to remove dimethylformamide. This process was performed twice. Through the above process, a Rink amide MBHA resin was prepared.
480 mL of 20% piperidine was added to the resin prepared in Example 1, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected Rink amide MBHA resin, was obtained.
In a vessel, 43.6 g of Cys(Trt)-Fmoc, 16.7 g of 1H-benzotriazole, 1-hydroxy, hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Cys(Trt)-Fmoc, was activated.
Cys(Trt)-Fmoc activated in step (2) was added to the Fmoc-deprotected Rink amide MBHA resin prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (poly 2mer synthesis) prepared in Synthesis 1 above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt) was obtained.
In a vessel, 29.6 g of Thr(tBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Thr(tBu)-Fmoc, was activated.
Thr(tBu)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Fmoc(C), was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 2mer) prepared in Synthesis 2 above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu) was obtained.
In a vessel, 44.4 g of Asn(Trt)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Thr(tBu)-Fmoc, was activated.
Asn(Trt)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 3mer) prepared in Synthesis 3) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt) was obtained.
In a vessel, 27.6 g of Met-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Met-Fmoc, was activated.
Met-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 4mer) prepared in Synthesis 4) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met was obtained.
In a vessel, 26.3 g of Leu-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Leu-Fmoc, was activated.
Leu-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 5mer) prepared in Synthesis 5) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu was obtained.
In a vessel, 39.2 g of Trp(Boc)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Trp(Boc)-Fmoc, was activated.
Trp(Boc)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 6mer) prepared in Synthesis 6) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc) was obtained.
In a vessel, 45.4 g of Gln(Trt)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Gln(Trt)-Fmoc, was activated.
Gln(Trt)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 7mer) prepared in Synthesis 7) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt) was obtained.
In a vessel, 45.4 g of Val-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Val-Fmoc, was activated.
Val-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 8mer) prepared in Synthesis 8) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val was obtained.
In a vessel, 28.2 g of Phe-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Phe-Fmoc, was activated.
Phe-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 9mer) prepared in Synthesis 9) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val was obtained.
In a vessel, 31.6 g of Glu(OtBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Glu(OtBu)-Fmoc, was activated.
Glu(OtBu)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 10mer) prepared in Synthesis 10) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu) was obtained.
In a vessel, 33.7 g of Lys(Alloc)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Lys(Alloc)-Fmoc, was activated.
Lys(Alloc)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 11 mer) prepared in Synthesis 11) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc) was obtained.
In a vessel, 23.2 g of Ala-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Ala-Fmoc, was activated.
Ala-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 12mer) prepared in Synthesis 12) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala, was obtained.
In a vessel, 48.3 g of Arg(Pbf)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Arg(Pbf)-Fmoc, was activated.
Arg(Pbf)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 13mer) prepared in Synthesis 13) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf), was obtained.
In a vessel, 34.9 g of Lys(Boc)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Lys(Boc)-Fmoc, was activated.
Lys(Boc)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the polypeptide (synthesis of poly 14mer) prepared in Synthesis 14) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc) was obtained.
In a vessel, 30.5 g of Glu(OAII)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Glu(OAII)-Fmoc, was activated.
Glu(OAII)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Fmoc, was obtained.
In a vessel, 11.5 g of tetrakispalladium and 800 mL of dichloromethane were added, and the mixture was completely dissolved by stirring. 78.6 mL of N-methylaniline and 38.5 mL of phenylsilane were added to the dissolved reaction solution, and the mixture was stirred for 5 minutes. 480 mL of dichloromethane was added to the polypeptide (synthesis of poly 15mer) prepared in Synthesis 15), stirred for 2 minutes, and then filtered. This process was performed three times. The thus-prepared reaction solution was added to the filtered resin, stirred at room temperature for 5 hours, and then filtered. 480 mL of dichloromethane was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed five times. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed twice.
The cyclization step can be carried out by way of the process of either (2)-1 or (2)-2 below.
In a vessel, 1H-benzotriazole, 1-hydroxy, 26.8 g of hydrate and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 27.2 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 5 minutes. The thus-prepared reaction solution was added to the polypeptide (partially deprotected 15mer) prepared in step (1), stirred at room temperature for 5 hours, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Fmoc, was obtained.
In a reaction vessel, 480 mL of dimethylformamide and 56.6 g of HATU(1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]-pyridinium 3-oxide) hexafluorophosphate) were added, and the mixture was completely dissolved by stirring. 51.8 mL of N,N-diisopropylethylamine was added to the dissolved reaction solution and stirred at room temperature for 5 minutes. The thus-prepared reaction solution was added to the polypeptide (partially deprotected 15mer) prepared in step (1), stirred at room temperature for 3 hours, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 15mer) prepared in Example 3 above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu], was obtained.
In a vessel, 30.6 g of Asp(OtBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Asp(OtBu)-Fmoc, was activated.
Asp(OtBu)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu] prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 16mer) prepared in Synthesis 1) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu), was obtained.
In a vessel, 26.3 g of Leu-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Leu-Fmoc, was activated.
Leu-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 17mer) prepared in Synthesis 2) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu, was obtained.
In a vessel, 34.2 g of Tyr(tBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Tyr(tBu)-Fmoc, was activated.
Tyr(tBu)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 18mer) prepared in Synthesis 3) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu), was obtained.
In a vessel, 34.9 g of Lys(Boc)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Lys(Boc)-Fmoc, was activated.
Lys(Boc)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 19mer) prepared in Synthesis 4) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc), was obtained.
In a vessel, 28.5 g of Ser(tBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Ser(tBu)-Fmoc, was activated.
Ser(tBu)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 20mer) prepared in Synthesis 5) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu), was obtained.
In a vessel, 34.2 g of Tyr(tBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Tyr(tBu)-Fmoc, was activated.
Tyr(tBu)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 21mer) prepared in Synthesis 6) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu), was obtained.
In a vessel, 30.6 g of Asp(OtBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Asp(OtBu)-Fmoc, was activated.
Asp(OtBu)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 22mer) prepared in Synthesis 7) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu), was obtained.
In a vessel, 28.5 g of Ser(tBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Ser(tBu)-Fmoc, was activated.
Ser(tBu)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 23mer) prepared in Synthesis 8) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu), was obtained.
In a vessel, 29.6 g of Thr(tBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Thr(tBu)-Fmoc, was activated.
Thr(tBu)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 24mer) prepared in Synthesis 9) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu), was obtained.
In a vessel, 28.8 g of Phe-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Phe-Fmoc, was activated.
Phe-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 25mer) prepared in Synthesis 10) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe, was obtained.
In a vessel, 29.6 g of Thr(tBu)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Thr(tBu)-Fmoc, was activated.
Phe-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 26mer) prepared in Synthesis 11) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu), was obtained.
In a vessel, 22.1 g of Gly-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Gly-Fmoc, was activated.
Gly-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 27mer) prepared in Synthesis 12) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly, was obtained.
In a vessel, 45.4 g of Gln(Trt)-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Gln(Trt)-Fmoc, was activated.
Gln(Trt)-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt)-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 28mer) prepared in Synthesis 13) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt), was obtained.
In a vessel, 24.2 g of Aib-Fmoc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Aib-Fmoc, was activated.
Aib-Fmoc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt) prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt)-Aib-Fmoc, was obtained.
480 mL of 20% piperidine was added to the cyclized polypeptide (synthesis of cyclized poly 29mer) prepared in Synthesis 14) above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt)-Aib, was obtained.
In a vessel, 37.0 g of His(Trt)-Boc, 16.7 g of 1-hydroxy-1H-benzotriazole hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 15.5 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, His(Trt)-Boc, was activated.
His(Trt)-Boc activated in step (2) was added to the Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt)-Aib prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt)-Aib-His(Trt)-Boc, was obtained.
165 mL of trifluoroacetic acid, 10 mL of phenol, 10 mL of distilled water, 10 mL of thioanisole, and 5 mL of 1,2-ethanedithiol were added to Vessel 2 under nitrogen atmosphere and stirred for 10 minutes. 20 g of the dried cyclized polypeptide 30mer was added to Vessel 1, and the prepared reaction solution was added thereto, and the mixture was stirred at room temperature for 1 hour and 30 minutes. 3.0 L of methyl tertiary butyl ether was added to Vessel 3 and cooled to 0° C. to 10° C. under nitrogen atmosphere. The temperature of the reaction solution of Vessel 1 was cooled to 5° C., and 2.0 L of methyl tertiary butyl ether, which is the cooled reactant in Vessel 3, was added thereto and stirred for 10 minutes. The reaction solution was filtered and washed twice with 400 mL of the cooled methyl tertiary butyl ether. The filtered crystals were dried under nitrogen atmosphere for 10 minutes. The thus-dried crystals were added to Vessel 1, and 400 mL of distilled water was added thereto, and the mixture was stirred at room temperature for 10 minutes. The reactant was filtered and washed with 600 mL of distilled water to obtain the target compound, NH2CO-Cys-Thr-Asn-Met-Leu-Trp-Gln-Val-Phe-Glu-cyclo[Lys-Ala-Arg-Lys-Glu]-Asp-Leu-Tyr-Lys-Ser-Tyr-Asp-Ser-Thr-Phe-Thr-Gly-Gln-Aib-His-NH2.TFA.
80.0 g (0.31 mmol/g) of Rink amide MBHA resin and 480 mL of dimethylformamide were added to a vessel, stirred for 15 minutes, and then filtered to remove dimethylformamide. This process was performed twice. Through the above process, Rink amide MBHA resin was prepared.
480 mL of 20% piperidine was added to the resin prepared in Comparative Example 1 above, stirred for 20 minutes, and then filtered to remove 20% piperidine. This process was performed twice. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, Fmoc-deprotected Rink amide MBHA resin, was obtained.
In a vessel, 29.1 g of Cys(Trt)-Fmoc, 1H-benzotriazole, 1-hydroxy, 13.4 g of hydrate, and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 11.6 mL of 1,3-diisopropylcarbodiimide was added to the dissolved reaction solution and stirred at room temperature for 30 minutes. Through the above process, the target compound, Cys(Trt)-Fmoc, was activated.
Cys(Trt)-Fmoc activated in step (2) was added to the Fmoc-deprotected Rink amide MBHA resin prepared in step (1), stirred at room temperature for 3 hours or more, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the above process, the target compound, resin-Cys(Trt)-Fmoc, was obtained.
The target compound, Fmoc-deprotected resin-Cys(Trt), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 1 mer) prepared in Synthesis 1).
The target compound, Thr(tBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 19.7 g of Thr(tBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Fmoc(C), was obtained in the same manner as in step (3) of Synthesis 1).
Step (1): Preparation of Fmoc Deprotection
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 2mer) prepared in Synthesis 2).
The target compound, Asn(Trt)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 29.6 g of Asn(Trt)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 3mer) prepared in Synthesis 3).
The target compound, Met-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 18.4 g of Met-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met, was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 4mer) prepared in Synthesis 4).
The target compound, Leu-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 17.5 g of Leu-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu, was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 5mer) prepared in Synthesis 5).
The target compound, Trp(Boc)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 26.1 g of Trp(Boc)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 6mer) prepared in Synthesis 6).
The target compound, Gln(Trt)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 30.3 g of Gln(Trt)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 7mer) prepared in Synthesis 7).
The target compound, Val-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 16.8 g of Val-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val, was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 8mer) prepared in Synthesis 8).
The target compound, Phe-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 19.2 g of Phe-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe, was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 9mer) prepared in Synthesis 9).
The target compound, Glu(OtBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 21.1 g of Glu(OtBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 10mer) prepared in Synthesis 10).
The target compound, Lys(Alloc)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 22.4 g of Lys(Alloc)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 11mer) prepared in Synthesis 11).
The target compound, Ala-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 15.4 g of Ala-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala, was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 12mer) prepared in Synthesis 12).
The target compound, Arg(Pbf)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 32.2 g of Arg(Pbf)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 13mer) prepared in Synthesis 13).
The target compound, Lys(Boc)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 23.2 g of Lys(Boc)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 14mer) prepared in Synthesis 14).
The target compound, Glu(OAII)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 20.3 g of Glu(OAII)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 15mer) prepared in Synthesis 15).
The target compound, Asp(OtBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 20.4 g of Asp(OtBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 16mer) prepared in Synthesis 16).
The target compound, Leu-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 17.5 g of Leu-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu, was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 17mer) prepared in Synthesis 17).
The target compound, Tyr(tBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 22.8 g of Tyr(tBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 18mer) prepared in Synthesis 18).
The target compound, Lys(Boc)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 23.2 g of Lys(Boc)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 19mer) prepared in Synthesis 19).
The target compound, Ser(tBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 19.0 g of Ser(tBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 20mer) prepared in Synthesis 20).
The target compound, Tyr(tBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 22.8 g of Tyr(tBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 21mer) prepared in Synthesis 21).
The target compound, Asp(OtBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 20.4 g of Asp(OtBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 22mer) prepared in Synthesis 22).
The target compound, Ser(tBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 19.0 g of Ser(tBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)- Ser(tBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 23mer) prepared in Synthesis 23).
The target compound, Thr(tBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 19.7 g of Thr(tBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)- Ser(tBu)-Thr(tBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 24mer) prepared in Synthesis 24).
The target compound, Phe-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 19.2 g of Phe-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe- Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)- Ser(tBu)-Thr(tBu)-Phe, was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 25mer) prepared in Synthesis 25).
The target compound, Thr(tBu)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 19.7 g of Thr(tBu)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe- Thr(tBu)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-SertBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)- Thr(tBu)-Phe-Thr(tBu), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 26mer) prepared in Synthesis 26).
The target compound, Gly-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 14.7 g of Gly-Fmoc.
The target compound, Resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe- Thr(tBu)-Gly-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)- Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly, was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 27mer) prepared in Synthesis 27).
The target compound, Gln(Trt)-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 30.3 g of Gln(Trt)-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe- Thr(tBu)-Gly-Gln(Trt)-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)- Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt), was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 28mer) prepared in Synthesis 28).
The target compound, Aib-Fmoc, was activated in the same manner as in step (2) of Synthesis 1) with 16.1 g of Aib-Fmoc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe- Thr(tBu)-Gly-Gln(Trt)-Aib-Fmoc, was obtained in the same manner as in step (3) of Synthesis 1).
The target compound, Fmoc-deprotected resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)- Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt)-Aib, was obtained in the same manner as in step (1) of Synthesis 1) with the polypeptide (synthesis of poly 29mer) prepared in Synthesis 29).
The target compound, His(Trt)-Boc, was activated in the same manner as in step (2) of Synthesis 1) with 30.7 g of His(Trt)-Boc.
The target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-Lys(Alloc)-Ala-Arg(Pbf)-Lys(Boc)-Glu(OAII)-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe- Thr(tBu)-Gly-Gln(Trt)-Aib-His(Trt)-Boc, was obtained in the same manner as in step (3) of Synthesis 1).
In a vessel, 11.5 g of tetrakispalladium and 800 mL of dichloromethane were added, and the mixture was completely dissolved by stirring. 78.6 mL of N-methylaniline and 38.5 mL of phenylsilane were added to the dissolved reaction solution and stirred for 5 minutes. 480 mL of dichloromethane was added to the polypeptide (synthesis of poly 30mer) prepared in Synthesis 30), stirred for 2 minutes, and then filtered. This process was performed three times. The thus-prepared reaction solution was added to the filtered resin, stirred at room temperature for 5 hours, and then filtered. 480 mL of dichloromethane was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed five times. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed twice.
In a vessel, 56.6 g of HATU and 480 mL of dimethylformamide were added, and the mixture was completely dissolved by stirring. 51.8 mL of N,N-diisopropylethylamine was added to the dissolved reaction solution and stirred at room temperature for 5 minutes. The thus-prepared reaction solution was added to the polypeptide (partially deprotected 30mer) prepared in step (1), stirred at room temperature for 3 hours, and then filtered. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. 480 mL of methanol was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. 480 mL of dimethylformamide was added to the filtered resin, stirred for 2 minutes, and then filtered. This process was performed three times. Through the process, the target compound, resin-Cys(Trt)-Thr(tBu)-Asn(Trt)-Met-Leu-Trp(Boc)-Gln(Trt)-Val-Phe-Glu(OtBu)-cyclo[Lys-Ala-Arg(Pbf)-Lys(Boc)-Glu]-Asp(OtBu)-Leu-Tyr(tBu)-Lys(Boc)-Ser(tBu)-Tyr(tBu)-Asp(OtBu)-Ser(tBu)-Thr(tBu)-Phe-Thr(tBu)-Gly-Gln(Trt)-Aib-His(Trt)-Boc, which is a cyclized polypeptide, was obtained.
The target compound, NH2-Cys-Thr-Asn-Met-Leu-Trp-Gln-Val-Phe-Glu-cyclo[Lys-Ala-Arg-Lys-Glu]-Asp-Leu-Tyr-Lys-Ser-Tyr-Asp-Ser-Thr-Phe-Thr-Gly-Gln-Aib-His-H.TFA was obtained in the same manner as in Example 4.
In the chromatogram of
As can be seen from the results summarized in Tables 1 and 2, the Example according to the present invention showed a much improved result (improved by about 7.5 times) compared to the Comparative Example of the prior art in which cyclization was performed after linear synthesis. In addition, it was confirmed that the specific gravity of related substances in the process was reduced by half relative to the maximum single related substance (see ratio and crude purity of maximum single related substances of Table 1). In terms of the types of the maximum single related substances, the maximum single related substance of the Comparative Example had an RRT of 1.12, but the related substance of the Example had an RRT of 0.86, which was further away from the main product peak (marked in the box of
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2019-0017766 | Feb 2019 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2020/002084 | 2/14/2020 | WO | 00 |
